News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Curis, Inc. (CRIS) Plunges as Death Forces FDA to Slap Partial Hold on Experimental Cancer Drug; Stock Falls -26.48% at Market Close (November 6, 2013)



11/6/2013 7:25:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Curis Inc said it had been stopped from enrolling any new patients in an early stage trial of its experimental cancer drug following the death of a patient who had liver failure. Curis's shares fell 10 percent in premarket trading after the U.S. Food and Drug Administration placed a partial hold on the trial. The company said the FDA was seeking additional data on patients treated with the drug, CUDC-427.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Xconomy


comments powered by Disqus
Reuters
Xconomy
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES